Skip to main content
OpenTrials
Completed

NCT Number: NCT07646093

Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children

**Brief Summary**

This study aimed to develop and conduct a preliminary clinical evaluation of a novel weight-adjusted gelatin-based diclofenac potassium medicated lollipop for the management of postoperative pain following adenotonsillectomy in children. The formulation was designed to improve analgesic adherence by providing a palatable and child-friendly dosage form suitable for oral transmucosal administration. Fifty paediatric patients aged 4 to 12 years undergoing elective adenotonsillectomy received one of three weight-adjusted diclofenac potassium lollipop doses (15 mg, 20 mg, or 30 mg) every 8 hours during the first 24 postoperative hours. The study assessed postoperative pain intensity, product acceptability, rescue analgesic use, and safety. In parallel, the formulation underwent pharmaceutical characterization, including physicochemical and microbiological quality evaluation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitario de Caracas

Caracas, Miranda, 1040, Venezuela

About this study

This prospective single-arm pilot study evaluated a newly developed gelatin-based diclofenac potassium medicated lollipop intended for postoperative pain management after paediatric adenotonsillectomy. The pharmaceutical formulation was optimized through iterative development and characterized by physicochemical testing, content uniformity analysis, and microbiological quality assessment according to pharmacopeial standards.

Children aged 4 to 12 years undergoing elective adenotonsillectomy received weight-adjusted diclofenac potassium lollipops (15 mg, 20 mg, or 30 mg) administered every 8 hours during the first 24 postoperative hours. Pain intensity was assessed before and after each dose using age-appropriate validated pain scales. Secondary evaluations included product acceptability, requirement for rescue analgesia, and occurrence of adverse events.

The study was designed as an exploratory pilot investigation to assess the feasibility, pharmaceutical performance, preliminary clinical effectiveness, and safety of this novel paediatric drug-delivery platform, providing the basis for future randomized controlled trials and pharmacokinetic evaluation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 4 to 12 years.
  • Scheduled for elective adenotonsillectomy under general anaesthesia.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Ability to tolerate oral administration of the medicated lollipop after surgery.
  • Written informed consent obtained from a parent or legal guardian.

Exclusion criteria

  • Known hypersensitivity or contraindication to diclofenac or other non-steroidal anti-inflammatory drugs.
  • History of asthma precipitated by NSAIDs.
  • Active gastrointestinal ulcer disease or gastrointestinal bleeding.
  • Significant hepatic, renal, cardiovascular, or coagulation disorders.
  • Severe developmental delay or neurological conditions preventing reliable pain assessment.
  • Requirement for postoperative intensive care admission.
  • Refusal of participation by the patient or parent/legal guardian.

Treatment and study plan

Diclofenac Potassium Medicated Lollipop

Drug

A weight-adjusted gelatin-based diclofenac potassium medicated lollipop formulated for paediatric postoperative analgesia. Three dosage strengths (15 mg, 20 mg, and 30 mg) were administered according to body weight every 8 hours during the first 24 postoperative hours following adenotonsillectomy.

Other names: DICLOPOP

Primary outcomes

  1. Postoperative Pain Intensity

    Time frame: 24 hours post operative

    Postoperative pain intensity assessed using a 10-point Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater postoperative pain intensity following administration of weight-adjusted diclofenac potassium medicated lollipops

Sponsors and collaborators

Lead sponsor

Hospital Universitario de Caracas

Other

Registry information

Official study title

Development and Preliminary Clinical Evaluation of a Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain Management in Paediatric Patients

Acronym: DICLOPOP

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 12, 2026
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.